Eleven of the 15 top-selling brand drugs in the United States are now subject to manufacturer-imposed 340B pricing restrictions, including eight in the past 90 days, a new analysis shows.
Real Chemistry, a health sector communications consulting firm, published the findings in its Feb. 1 private daily email to clients. Brian Reid, leader of the firm’s corporate pricing and public affairs practice, tweeted a chart showing the figures. We are re-publishing the data with his permission.
Eleven of the 15 top-selling brand drugs in the United States are now subject to manufacturer-imposed 340B pricing restrictions, including eight in the past 90 days, a new analysis shows.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
